FOXO Technologies

Modernizing the longevity insurance industry with molecular biotechnology

FOXO Technologies is transforming the global longevity insurance industry with a next-generation underwriting protocol and consumer engagement platform based on epigenetic technology and insights.FOXO Technologies Inc. uses AI-driven bioinformatics and microarray technologies to develop and commercialize epigenetic biomarkers of health and aging.

FOXO provides insurers, health researchers, and life science companies with laboratory services, microarray design, and AI-driven bioinformatics software solutions for generating novel health-based insights into lifespan.

Details last updated 24-Apr-2021

FOXO Technologies News

FOXO3: the longevity gene that shapes lifespan

Forbes - 04-Jan-2024

Scientists explore how this key gene affects aging—and how lifestyle may activate its benefits

FOXO licenses use of epigenetic clocks in life insurance industry

Longevity Technology - 05-May-2021

Modernizing life insurance to keep its customers healthy and alive

FOXO Technologies is also referenced in the following:

ARDD 2021 - 8th Aging Research and Drug Discovery Meeting

31-Aug-2021 to 03-Sep-2021

Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.

People at FOXO Technologies